Aarti Drugs Limited
6,063words
5turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
Rs. 100
crore
Rs.
2,700
Rs. 2,000
Rs.
200
Rs. 200
Rs. 1,000 crore
100%
Rs. 100 crore
4,261
MT
38%
85%
Guidance — 1 items
Empowerment
opening
“• CRAMS industry has posted 48% CAGR between FY15-18 and expected to witness a strong growth over 25% over 2018-21 Formulations Biosimilars • Largest exporter of formulations in terms of volume, with 14% market share and 12th in terms of export value.”
Advertisement
Risks & concerns — 1 flagged
stringent product quality control, strict QA and QC dept to ensure that product is at the mark of the quality as per various pharma copeial standards • The Board has an optimum combination of Executive and Non-Executive directors and gender diversification • Risk Management Governance • Occupational Healthy Policy • Policies governing related party transactions • In compliance with all regulatory requirement of the Audit Committee • Mechanism of Stakeholders Board.
— Empowerment
Speaking time
1
1
1
1
1
Advertisement
Opening remarks
Empowerment
Free Government approved and certified vocational course training for women to generate employment. • Healthcare: Primary Healthcare Infrastructure Development and Improvement around the manufacturing facilities. • Gender Diversity: ~40% women staff at HO, contributing in various departments such as marketing, factory level, women are employed at QC QA, regulatory affairs, etc. departments. finance, procurement. At • Stakeholder Management: No unfair trade practices events in the last 5 years. stringent product quality control, strict QA and QC dept to ensure that product is at the mark of the quality as per various pharma copeial standards • The Board has an optimum combination of Executive and Non-Executive directors and gender diversification • Risk Management Governance • Occupational Healthy Policy • Policies governing related party transactions • In compliance with all regulatory requirement of the Audit Committee • Mechanism of Stakeholders Board. periodic Relationship reporting
Barriers
Presence in Highly Specialized API Segment 2. Unique Competitive Position 6. Capex to drive the next leg of growth 3. Poised to overcome industry challenges 5. Robust Balance Sheet 4. Diversified product and client mix High Entry Barriers : Presence in Highly Specialized API Segment Over a decade, API manufacturing has transitioned towards highly regulated, specialized business How API Manufacturing Has Evolved Impact Regulations ❑ Stringent pharmacopoeia standards ❑ Addition of elemental ❑ Tightened impurity profiling ❑ Rigorous carcinogenicity checks Cost Structure Higher capex requirements to adhere to ever rising quality, environmental & regulatory requirements High R&D costs Tightened Regulations Quality & Environmental Standards Higher Capex Requirements ❑ Lower Competitive Intensity: Various small-scale manufacturers have exited due to unviability of cost structure ❑ High Entry Barriers: High entry barriers for new entrants due to cost structure and compliance requirements ❑ API
Captive consumption
Rs. 300 crores Revenue Growth Higher Margins Higher RoCE 29 Product-wise Capex Plans Anti Diabetic ▪ CEP renewed by EDQM in 2022 ▪ Manufacturing over 1,000 TPM making it one of the largest metformin player ▪ Coming up with 1450 TPM capacity via brown field expansion in Q1FY24 ▪ Launch of Gliptins will further strengthen this therapeutic category. ▪ Exploring backward integration options. Antiprotozoal ▪ Further consolidating the position in Indian Market via brown field expansion by about 40% for couple of products ▪ Recently got approval to market the product in China ▪ Incremental expansions and downstream products improvement Vitamins / Anti- Inflammatory ▪ Multi-purpose facility under construction. Targeting highly regulated markets. ▪ Brown field expansion of its existing anti inflammatory products commissioned at the end of FY20 which will drive future growth in this therapeutic category ▪ Installed capacity will give revenues of around Rs. 50 crores / Rs. 35 crores per annum as
Investor Relations Advisor
CIN: L37060MH1984PLC055433 CIN: U74140MH2010PTC204285 Mr. Rushikesh Deole Email: investorrelations@aartidrugs.com Contact no.: +91 22 24048199 Mr. Jigar Kavaiya / Mr. Chinmay Madgulkar E: jigar.kavaiya@sgapl.net / chinmay.m@sgapl.net T: +91 9920602034 / +91 9860088296 www.aartidrugs.com www.sgapl.net
Advertisement